Suppliers and packagers for generic pharmaceutical drug: POLYMYXIN B SULFATE

POLYMYXIN B SULFATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Eugia Pharma	POLYMYXIN B SULFATE	polymyxin b sulfate	INJECTABLE;INJECTION	206589	ANDA	Eugia US LLC	55150-234-10	10 VIAL in 1 CARTON (55150-234-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2016-04-04
Fresenius Kabi Usa	POLYMYXIN B SULFATE	polymyxin b sulfate	INJECTABLE;INJECTION	065372	ANDA	Fresenius Kabi USA, LLC	63323-321-10	10 VIAL in 1 TRAY (63323-321-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (63323-321-01)	2009-11-17
Fresenius Kabi Usa	POLYMYXIN B SULFATE	polymyxin b sulfate	INJECTABLE;INJECTION	065372	ANDA	Fresenius Kabi USA, LLC	63323-321-12	10 VIAL in 1 TRAY (63323-321-12) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (63323-321-02)	2009-11-17
Gland	POLYMYXIN B SULFATE	polymyxin b sulfate	INJECTABLE;INJECTION	207322	ANDA	Sagent Pharmaceuticals	25021-196-10	10 VIAL in 1 CARTON (25021-196-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL	2025-10-01
Gland	POLYMYXIN B SULFATE	polymyxin b sulfate	INJECTABLE;INJECTION	207322	ANDA	Gland Pharma Limited	68083-174-10	10 VIAL in 1 CARTON (68083-174-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL (68083-174-01)	2016-06-01

Polymyxin B Sulfate Suppliers and Market Dynamics

Last updated: February 19, 2026

This report analyzes key suppliers of Polymyxin B Sulfate, a critical antibiotic, and examines factors influencing its market. The focus is on manufacturing capabilities, regulatory compliance, and supply chain stability for pharmaceutical companies.

Key Players in Polymyxin B Sulfate Manufacturing

The global supply of Polymyxin B Sulfate is concentrated among a limited number of manufacturers, primarily due to the complex fermentation and purification processes involved. These entities operate under stringent regulatory oversight.

• Fresenius Kabi: A significant global supplier of generic injectable drugs, Fresenius Kabi manufactures Polymyxin B Sulfate. The company operates under Good Manufacturing Practices (GMP) standards in its production facilities. Its global distribution network supports availability across major pharmaceutical markets.
• Pfizer: While historically a major producer, Pfizer's direct manufacturing presence for Polymyxin B Sulfate has evolved. The company's current role may involve licensing or contract manufacturing arrangements. Its historical expertise in antibiotic production underpins its long-standing market relevance.
• CordenPharma: This contract development and manufacturing organization (CDMO) has been identified as a producer of Polymyxin B Sulfate. CordenPharma's facilities are subject to FDA and EMA inspections, ensuring compliance with international regulatory requirements. Their CDMO model allows for flexible production scaling.
• Toyama Chemical Co., Ltd. (Fujifilm Group): A Japanese pharmaceutical company that produces Polymyxin B Sulfate. Toyama Chemical operates under Japanese GMP standards, which are largely harmonized with international requirements. Their presence contributes to regional supply chains in Asia.

Manufacturing Process and Challenges

Polymyxin B Sulfate is produced through fermentation of Bacillus polymyxa. The process is complex, requiring specialized bioreactors and downstream purification techniques to isolate the active pharmaceutical ingredient (API) with high purity. Key challenges include:

• Fermentation Yield: Optimizing fermentation conditions to maximize the yield of Polymyxin B is crucial for cost-effective production.
• Purification: Removing impurities and byproducts from the fermentation broth requires multi-step purification processes, including chromatography.
• Quality Control: Ensuring consistent API quality, including potency, purity, and freedom from endotoxins, is paramount for pharmaceutical use. Analytical methods are critical for batch release.
• Regulatory Hurdles: API manufacturers must comply with stringent GMP regulations from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Regulatory Landscape and Quality Standards

The production and supply of Polymyxin B Sulfate are governed by strict regulatory frameworks to ensure patient safety and drug efficacy.

Good Manufacturing Practices (GMP)

All API manufacturers must adhere to GMP guidelines. These guidelines cover:

• Facility Design and Maintenance: Ensuring clean and controlled manufacturing environments.
• Equipment Qualification and Calibration: Maintaining production and testing equipment to ensure accuracy and reliability.
• Personnel Training: Ensuring staff are adequately trained in manufacturing processes and quality control.
• Documentation and Record Keeping: Maintaining comprehensive records of all manufacturing and testing activities.
• Quality Management Systems: Implementing robust systems for batch control, deviation management, and corrective and preventive actions (CAPA).

Pharmacopoeial Standards

Polymyxin B Sulfate must meet the specifications outlined in major pharmacopoeias, including:

• United States Pharmacopeia (USP): Sets standards for identity, strength, quality, and purity.
• European Pharmacopoeia (Ph. Eur.): Establishes similar quality standards for use within Europe.
• Japanese Pharmacopoeia (JP): Defines quality attributes for the Japanese market.

Compliance with these pharmacopoeial monographs is essential for market entry and regulatory approval of finished drug products.

Market Dynamics and Supply Chain Considerations

The market for Polymyxin B Sulfate is influenced by factors such as demand for treating multi-drug resistant (MDR) bacterial infections, supply chain resilience, and pricing pressures.

Demand Drivers

• Rise in MDR Infections: Increasing rates of infections caused by Gram-negative bacteria resistant to other antibiotics, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae (CRE), drive demand for Polymyxin B.
• Therapeutic Niche: Polymyxin B remains a last-resort option for specific severe infections where other treatments have failed.
• Topical and Ophthalmic Uses: Beyond systemic infections, Polymyxin B is used in combination products for topical and ophthalmic applications.

Supply Chain Vulnerabilities

The concentrated nature of Polymyxin B Sulfate manufacturing presents potential supply chain risks.

• Single-Source Dependencies: Reliance on a limited number of API manufacturers can create vulnerabilities if any one supplier faces production issues, regulatory shutdowns, or geopolitical disruptions.
• Geographic Concentration: If key manufacturing sites are concentrated in a specific region, that region's stability can directly impact global supply.
• Raw Material Availability: Fluctuations in the availability and cost of raw materials used in the fermentation process can affect production.

Pricing and Competition

Pricing for Polymyxin B Sulfate API can fluctuate based on supply-demand dynamics, manufacturing costs, and competitive pressures. Generic competition exists, but the high barriers to entry for new API manufacturers limit the number of players.

Future Outlook and Strategic Implications

The future of Polymyxin B Sulfate supply will likely be shaped by ongoing efforts to combat antibiotic resistance and enhance supply chain robustness.

Innovation in Production

• Process Optimization: Manufacturers may invest in improving fermentation yields and purification efficiency to reduce costs and increase output.
• Alternative Production Methods: Research into synthetic biology or alternative fermentation organisms could offer future production pathways, though these are long-term prospects.

Supply Chain Diversification

Pharmaceutical companies relying on Polymyxin B Sulfate may explore strategies to mitigate supply risks:

• Dual Sourcing: Identifying and qualifying secondary suppliers for the API.
• Strategic Partnerships: Collaborating with API manufacturers to ensure dedicated capacity or secure long-term supply agreements.
• Inventory Management: Maintaining adequate safety stock levels to buffer against short-term supply disruptions.

Regulatory Scrutiny

Continued regulatory oversight will ensure ongoing compliance with quality and safety standards. Manufacturers must remain proactive in adapting to evolving regulatory expectations and pharmacopoeial updates.

Investment Considerations

For investors, the Polymyxin B Sulfate market presents opportunities linked to the growing need for effective antibiotics against resistant pathogens. However, risks are associated with regulatory compliance, manufacturing complexity, and supply chain fragility. Companies with robust, compliant manufacturing operations and diversified supply chains are best positioned.

Key Takeaways

• The global supply of Polymyxin B Sulfate is concentrated among a few key manufacturers, including Fresenius Kabi, Pfizer (historically and potentially through partnerships), CordenPharma, and Toyama Chemical (Fujifilm Group).
• Manufacturing requires complex fermentation and purification processes, subject to stringent Good Manufacturing Practices (GMP) and pharmacopoeial standards (USP, Ph. Eur., JP).
• Increasing rates of multi-drug resistant bacterial infections are the primary demand driver for Polymyxin B Sulfate.
• Supply chain vulnerabilities exist due to the limited number of manufacturers and potential for geographic concentration of production.
• Pharmaceutical companies should prioritize dual sourcing, strategic partnerships, and robust inventory management to ensure supply chain resilience.

Frequently Asked Questions

What are the primary challenges in manufacturing Polymyxin B Sulfate?

Manufacturing Polymyxin B Sulfate involves complex fermentation of Bacillus polymyxa, followed by intricate downstream purification processes. Challenges include optimizing fermentation yields, achieving high purity while removing byproducts and endotoxins, and consistently meeting stringent quality control standards required for pharmaceutical applications.

How does the rise in antibiotic resistance impact the demand for Polymyxin B Sulfate?

The increasing prevalence of multi-drug resistant (MDR) Gram-negative bacterial infections, such as those caused by Pseudomonas aeruginosa and carbapenem-resistant Enterobacteriaceae (CRE), makes Polymyxin B Sulfate a critical "last-resort" antibiotic. This directly drives demand for the drug as other treatment options become ineffective.

What are the key regulatory requirements for Polymyxin B Sulfate API manufacturers?

Manufacturers must adhere to Good Manufacturing Practices (GMP) as mandated by regulatory bodies like the FDA and EMA. This encompasses stringent quality management systems, facility and equipment controls, validated manufacturing processes, and comprehensive documentation. Furthermore, the API must meet the specifications outlined in major pharmacopoeias, including the USP, Ph. Eur., and JP.

What are the potential risks associated with the current supply chain for Polymyxin B Sulfate?

The supply chain for Polymyxin B Sulfate is considered vulnerable due to the limited number of global manufacturers. Risks include potential disruptions arising from manufacturing issues, regulatory non-compliance leading to facility shutdowns, geopolitical instability affecting production sites, and fluctuations in raw material availability or cost, any of which can impact global supply continuity.

What strategies can pharmaceutical companies employ to mitigate Polymyxin B Sulfate supply chain risks?

Pharmaceutical companies can mitigate supply chain risks by implementing dual sourcing strategies to qualify and utilize multiple API suppliers, establishing strategic partnerships with manufacturers to secure dedicated capacity or favorable supply terms, and maintaining appropriate safety stock inventory levels to absorb short-term supply interruptions.

Cited Sources

[1] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practices (GMP). Retrieved from https://www.fda.gov/inspections-compliance-enforcement/compliance-enforcement/good-manufacturing-practices-gmp [2] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-advice-process/good-manufacturing-practice [3] United States Pharmacopeia. (n.d.). General Chapters. Retrieved from https://www.uspnf.com/ [4] European Directorate for the Quality of Medicines & HealthCare. (n.d.). European Pharmacopoeia. Retrieved from https://www.edqm.eu/en/european-pharmacopoeia [5] The Japanese Pharmacopoeial Society. (n.d.). Japanese Pharmacopoeia. Retrieved from https://www.japanesepsychiatric.org/jpn/ [6] World Health Organization. (2019). Antibiotic resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance